<DOC>
	<DOCNO>NCT02142218</DOCNO>
	<brief_summary>The purpose program provide treatment nivolumab subject Stage III Stage IV advance melanoma .</brief_summary>
	<brief_title>Expanded Access Program With Nivolumab Treat Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com ECOG Performance Status 01 Histologically confirm malignant melanoma Progressed treatment antiCTLA4 Active brain metastasis Life Expectancy &lt; 6 week Subjects receive prior therapy target Tcell costimulation checkpoint pathway except Anti CTLA4 therapy Subjects autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>